By Colin Kellaher

 

Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Friday said is seeking approval from the European Medicines Agency for subcutaneous use of Darzalex in patients with multiple myeloma.

Darzalex is currently only approved for intravenous use.

Janssen said subcutaneous Darzalex is co-formulated with Halozyme Therapeutics Inc.'s (HALO) Enhanze drug-delivery technology.

Janssen last week filed for U.S. Food and Drug Administration approval for the subcutaneous formulation of Darzalex in multiple myeloma, a cancer that forms in a type of white blood cells called plasma cells and causes cancer cells to accumulate in the bone marrow.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

July 19, 2019 07:30 ET (11:30 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Halozyme Therapeutics Charts.
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Halozyme Therapeutics Charts.